Description: Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Home Page: www.vorbio.com
VOR Technical Analysis
100 Cambridgepark Drive
Cambridge,
MA
02140
United States
Phone:
617 655 6580
Officers
| Name | Title |
|---|---|
| Dr. Robert Ang M.B.A., M.D., MBBS | Pres, CEO & Director |
| Dr. Tirtha Chakraborty Ph.D. | Chief Scientific Officer |
| Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D. | Scientific Founder & Chairman of Scientific Advisory Board |
| Dr. Nathan D. Jorgensen M.B.A., Ph.D. | Chief Financial Officer |
| Ms. Tania Philipp | Chief People Officer |
| Dr. Robert G. Pietrusko Pharm.D., Pharm. D. | Chief Regulatory & Quality Officer |
| Mr. John C. King M.B.A. | Chief Commercial Officer |
| Dr. Veit Schmelmer Ph.D. | Sr. VP of Program & Alliance Management |
| Dr. Eyal C. Attar M.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5785 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-02-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 135 |